[et_pb_section fb_built=”1″ specialty=”on” _builder_version=”4.16″ background_color=”#e0edf9″ global_colors_info=”{}”][et_pb_column type=”3_4″ specialty_columns=”3″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_row_inner _builder_version=”4.16″ custom_padding=”||13px|||” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Great news! We have reached an important milestone in the AGO-OP.11\/ ENGOT-en22\/ STREAM-I study: The 100th patient has been enrolled!<\/p>\n
This is a significant achievement for the AGO Study Group and all participating study centers. We would like to express our sincere gratitude to all study physicians, study nurses, and of course, the participating patients for their commitment.<\/p>\n
To provide you with a quick overview, an AI-based video has been created summarizing the key points of the study.<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/vimeo.com\/1047836199\/4520bc5fb5?share=copy” url_new_window=”on” button_text=”Link to the video” _builder_version=”4.27.4″ custom_button=”on” button_text_size=”18px” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.21.0″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n
Patients with low-risk early-stage cervical cancer were previously treated with major radical surgery. Radical surgery involves removing the uterus with adjacent connective tissue and upper part of the vagina to ensure that no tumor cells remain in the body. The SHAPE international comparative study investigated whether removing only the uterus increases the risk of recurrence. The SHAPE study was able to show that pure removal of the uterus is not only gentler for the women concerned, but actually brings them no disadvantages.<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2023\/06\/2023-008-Pressemitteilung_SHAPE_EN.pdf” url_new_window=”on” button_text=”DOWNLOAD Results of the SHAPE study” _builder_version=”4.21.0″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n
New inclusion criteria for BRCA1\/2 gene analysis and new forms of cross-sector collaboration \u2013 Ersatzkassen health insurers expand special offer for their insureds<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2020\/07\/presse_mitteilung_brca.pdf” url_new_window=”on” button_text=”DOWNLOAD New inclusion criteria for BRCA1\/2 gene analysis” _builder_version=”4.16″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ custom_padding=”||13px|||” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ header_font=”|700||on|||||” header_text_color=”#11487E” header_2_text_color=”#11487E” custom_margin=”||8px|||” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.17.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n
Prof. Dr. Dr. h.c. Andreas du Bois was once again honoured for his outstanding medical achievements on 24 October 2021. After receiving the German Cancer Award for excellent clinical research in 2020, he was now honoured by the ESGO (European Society of Gynaecological Oncology) with the “ESGO Lifetime Achievement Award” for his life’s work.<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2022\/06\/Honoured-for-his-lifes-work_du-Bois.pdf” url_new_window=”on” button_text=”DOWNLOAD ESGO Lifetime Achievement Award” _builder_version=”4.17.4″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.17.4″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n
Andreas du Bois is a leading expert in gynecologic oncology. He founded the AGO Study Group as a young senior physician, laying the foundation for the establishment of innovations in gynecologic oncology and improvements in therapeutic standards in ovarian cancer.<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2021\/07\/Deutscher-Krebspreis-2020-fuer-exzellente-klinische-Forschung_EN.docx.pdf” url_new_window=”on” button_text=”DOWNLOAD German Cancer Award 2020 ” _builder_version=”4.16″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n
Prof. Dr. med. Andreas du Bois is the winner of the 2006 Arthur Walpole Award, which comes with prize money of 10,250 euros. The award was conferred on the occasion of the German Cancer Congress on 26 March 2006 in Berlin. It is awarded every two years by the German Cancer Society [Deutsche Krebsgesellschaft e.V., DKG) to the best clinical trial from Germany (\u201cinnovative concept with pioneering research question and quality of study conduct\u201d).<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2021\/07\/walpole_preis_2006-EN.pdf” url_new_window=”on” button_text=”DOWNLOAD Arthur Walpole Award 2006″ _builder_version=”4.16″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.4em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n
At this year\u2019s annual meeting of the Austrian Working Group for Gynaecological Oncology in the Austrian Society for Gynecology and Obstetrics in Salzburg in May, the Ernst Wertheim Award was awarded to Professor Andreas du Bois, Director of the Clinic for Gynecology & Gynecological Oncology at the Dr. Horst Schmidt Clinics (HSK) Wiesbaden\u2026<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2021\/07\/wertheim_preis_2006_EN.pdf” url_new_window=”on” button_text=”DOWNLOAD Wertheim Award 2006 ” _builder_version=”4.16″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][et_pb_row_inner _builder_version=”4.16″ background_color=”#ffffff” custom_margin=”||32px|||” custom_padding=”5%|6%|5%|6%|true|true” animation_style=”slide” animation_direction=”bottom” animation_starting_opacity=”12%” global_colors_info=”{}”][et_pb_column_inner saved_specialty_column_type=”3_4″ _builder_version=”4.16″ global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ text_text_color=”#000000″ text_font_size=”16px” header_3_font=”|700|||||||” header_3_text_color=”#7ca9d6″ header_3_font_size=”20px” header_3_line_height=”1.4em” background_enable_color=”off” global_colors_info=”{}”]<\/p>\n
for \u2018A Randomized Clinical Trial of Cisplatin\/Paclitaxel Versus Carboplatin\/Paclitaxel as First-Line treatment of Ovarian Cancer\u2019\u2026<\/p>\n
[\/et_pb_text][et_pb_button button_url=”https:\/\/ago-ovar.de\/wp-content\/uploads\/2020\/09\/quality_of_life_price_2006.pdf” url_new_window=”on” button_text=”DOWNLOAD Quality of Life Award 2006 ” _builder_version=”4.16″ custom_button=”on” button_text_size=”18px” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_sidebar area=”et_pb_widget_area_4″ show_border=”off” admin_label=”Seitenleiste” _builder_version=”4.16″ header_text_color=”#000000″ body_font=”|700|||||||” body_text_color=”#ef5b21″ background_color=”rgba(255,255,255,0.6)” background_enable_color=”off” min_height=”257px” custom_padding=”8%|4%|4%|8%|false|false” saved_tabs=”all” global_colors_info=”{}”][\/et_pb_sidebar][\/et_pb_column][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Press ReleasesAGO-OP.11\/ ENGOT-en22\/ STREAM-I study Great news! We have reached an important milestone in the AGO-OP.11\/ ENGOT-en22\/ STREAM-I study: The 100th patient has been enrolled! This is a significant achievement for the AGO Study Group and all participating study centers. We would like to express our sincere gratitude to all study physicians, study nurses, and […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":881,"menu_order":40,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-905","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/comments?post=905"}],"version-history":[{"count":23,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/905\/revisions"}],"predecessor-version":[{"id":2308,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/905\/revisions\/2308"}],"up":[{"embeddable":true,"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/pages\/881"}],"wp:attachment":[{"href":"https:\/\/ago-ovar.de\/en\/wp-json\/wp\/v2\/media?parent=905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}